Genomics Bioscience & Technology Co

Genomics Bioscience & Technology Co Capital Expenditures

The Capital Expenditures (CapEx) of Genomics Bioscience & Technology Co (4195.TWO) as of Oct 21, 2026 is -84.86 M TWD. In the previous year, Capital Expenditures (CapEx) was -193.43 M TWD — a change of -56.13% (higher).

Capital Expenditures

-84.86 MTWD

YoY

-56.13%

Last updated:

Capital Expenditures (CapEx) of Genomics Bioscience & Technology Co is 2025 -84.86 M TWD. Capital Expenditures (CapEx) of Genomics Bioscience & Technology Co was 2024 -193.43 M TWD. It decreases by -56.13% higher compared to the previous year.

The Genomics Bioscience & Technology Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-18.59 M TWD
Jan 1, 2019
-20.98 M TWD
Jan 1, 2020
-46.44 M TWD
Jan 1, 2021
-94.81 M TWD
Jan 1, 2022
-94.23 M TWD
Jan 1, 2023
-151.37 M TWD
Jan 1, 2024
-193.43 M TWD
Jan 1, 2025
-84.86 M TWD
The Genomics Bioscience & Technology Co Capital Expenditures history
YEARCapital ExpendituresYoY
-84.86 MTWD-56.13%
-193.43 MTWD+27.78%
-151.37 MTWD+60.64%
-94.23 MTWD-0.61%
-94.81 MTWD+104.18%
-46.44 MTWD+121.36%
-20.98 MTWD+12.83%
-18.59 MTWD-64.25%
-52.01 MTWD+10.74%
-46.97 MTWD+565.79%
-7.05 MTWD-88.11%
-59.35 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomics Bioscience & Technology Co Stock analysis

What does Genomics Bioscience & Technology Co do? Genomics BioSci & Tech.Co., Ltd. generates revenue through the provision of public gene sequencing and clinical sequencing services, including preventive genetic testing, primer synthesis, and individualized medical and genetic screening for cancers. The company also manufactures and sells biochemical instruments, reagents, and consumables, distributing these products domestically and internationally. Its primary customers are healthcare providers and research institutions seeking genetic analysis and diagnostic solutions. The firm's services and products target both public health initiatives and specialized medical applications in oncology and preventive care. The company's revenue streams are derived from its core biotechnological services and product sales, with a focus on domestic and overseas markets. Public gene sequencing services cater to broader health screening needs, while clinical sequencing services address specific medical conditions, particularly cancer-related genetic screening. The firm's biochemical instruments and reagents support laboratory operations in both research and clinical settings, serving a diverse clientele across multiple healthcare segments. Genomics Bioscience & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomics Bioscience & Technology Co stock

Capital Expenditures (CapEx) of Genomics Bioscience & Technology Co is -84.86 M TWD in 2025.

Capital Expenditures (CapEx) of Genomics Bioscience & Technology Co changed from -193.43 M TWD to -84.86 M TWD, representing a -56.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Genomics Bioscience & Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genomics Bioscience & Technology Co

All Key Metrics — Genomics Bioscience & Technology Co